1 julio 2015
The SENRI trial has opened the window to evaluate NK1 antagonists for emesis prevention in patients taking oxaliplatin chemotherapy, results of a new study.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/BqUAdwCDVGA/150701093759.htm
